Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
PMID: 23114756
2013
Antimicrobial agents and chemotherapy
Abstract: Sanger sequencing identified >=1 LAM resistance mutations (rtL80I/V, rtM204I, and rtA181T) in samples from 5 (11%) of 46 LAM-experienced and none of 45 LAM-naive subjects (0%; P = 0.06).
Abstract: UDPS detected >=1 LAM resistance mutations (rtL80I/V, rtV173L, rtL180M, rtA181T, and rtM204I/V) in 10 (22%) of the 46 LAM-experienced subjects, including 5 in whom LAM resistance mutations were not identified by S
[Mutation analysis of the HBV reverse transcriptase in nucleos(t)ide-treated patients with chronic HBV infection].
PMID: 23627028
2012
Zhonghua shi yan he lin chuang bing du xue za zhi
Abstract: RtM204 mutations were detected at the highest frequency among 63 mutants (40/63, 63.49%) and found to display 11 combination mutation patterns, in which rtM204I were associated with rtL80I/V and rtL180M, and rtM204V were associated with rtL1l80M, respectively.
Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
Abstract: In HBV-D treated patients the dominant resistance mutation was rtL80V (31.4%) and rtM204I (60%) in LAM+ADV group while LAM-treated patients showed a preference of rtM204V (51.9%).
Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients.
Introduction: Compensatory mutations in the rt domain (rtL180M, rtV173L, rtL80I/V) that partially restore replication efficiency are often co-selected in HBV rt204 mutants.
rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.
PMID: 21777282
2012
Journal of gastroenterology and hepatology
Abstract: The rtL180M and rtL80V/I mutations were identified in 68% and 69%, respectively.
Abstract: There was no difference in the occurrence of VB with regard to types of YMDD mutation or rtL80V/I.
Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
Abstract: rtL80I/V-rtL180M-rtV173L), whilst most primary mutations (including rtM204V-rtA181T/V-rtI169T-rtA194T) are associated with low genetic barrier.
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs.
Abstract: HBV reverse-transcriptase (RT) region was sequenced and analyzed for 20 mutations, confirmed by in vitro studies as associated with resistance to nucleos(t)ide HBV-RT inhibitors (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C/G/I-
Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies.
Introduction: Some of these mutations can act as compensatory mutations, such as rtL80I/V and rtV173L.
Result: Four different LAM resistance patterns were identified in 84 out of 194 patients (43%): baseline primary mutation (rtM204I/V, n = 26), primary mutation with the compensatory mutations rtL80I/V (n = 16) or rtL180M (n = 24), triple mutant (rtM204I/V + rtV173L + rtL180M or rt<
HBV mutation literature information.
PMID: 
2013
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT